Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today

BioMarin Pharmaceutical (BMRN) is up 7.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is investor enthusiasm following BioMarin’s August 6 second-quarter 2026 update, which showed 20% year-over-year revenue growth and higher full-year guidance. The rally also appears supported by continued momentum around VOXZOGO, including stronger sales expectations and recent regulatory progress, though some of today’s move could be a delayed reaction rather than a single new announcement.

Details:

BioMarin reported second-quarter 2026 total revenue of $990 million, up 20% from a year earlier, helped by growth across its portfolio and contributions from newly added products.

The company raised full-year 2026 guidance for total revenue, VOXZOGO revenue, and non-GAAP diluted EPS, signaling stronger-than-expected operating momentum.

VOXZOGO remained a key bright spot, with the company lifting 2026 revenue guidance to at least $1 billion and noting that the number of children treated globally increased more than 20% year over year in the quarter.

BioMarin also recently said the FDA accepted its supplemental application for full approval of VOXZOGO in children with achondroplasia, adding another regulatory milestone for an important growth asset.

Sources:

BioMarin, U.S. Food and Drug Administration

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BMRN Insider Trading Activity

$BMRN insiders have traded $BMRN stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $BMRN stock by insiders over the last 6 months:

GEORGE ERIC DAVIS (EVP, Chief Legal Officer) sold 26,061 shares for an estimated $1,599,102
CHARLES GREG GUYER (EVP, Chief Technical Officer) sold 16,486 shares for an estimated $996,743
GREGORY R FRIBERG (EVP, Chief R&D Officer) sold 6,326 shares for an estimated $381,937

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive BMRN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BMRN Hedge Fund Activity

We have seen 263 institutional investors add shares of $BMRN stock to their portfolio, and 271 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC added 3,147,943 shares (+230.7%) to their portfolio in Q1 2026, for an estimated $177,827,300
FMR LLC added 1,729,960 shares (+94.2%) to their portfolio in Q1 2026, for an estimated $97,725,440
SQUAREPOINT OPS LLC removed 1,468,642 shares (-80.3%) from their portfolio in Q1 2026, for an estimated $82,963,586
BALYASNY ASSET MANAGEMENT L.P. added 1,362,752 shares (+inf%) to their portfolio in Q1 2026, for an estimated $76,981,860
DEEP TRACK CAPITAL, LP removed 1,150,000 shares (-50.0%) from their portfolio in Q1 2026, for an estimated $64,963,500
ARGA INVESTMENT MANAGEMENT, LP added 1,039,409 shares (+inf%) to their portfolio in Q2 2026, for an estimated $59,474,982
VIKING GLOBAL INVESTORS LP added 1,025,141 shares (+17.0%) to their portfolio in Q1 2026, for an estimated $57,910,215

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BMRN Analyst Ratings

Wall Street analysts have issued reports on $BMRN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Canaccord Genuity issued a "Buy" rating on 05/22/2026

To track analyst ratings and price targets for $BMRN, check out Quiver Quantitative's $BMRN forecast page.

$BMRN Price Targets

Multiple analysts have issued price targets for $BMRN recently. We have seen 14 analysts offer price targets for $BMRN in the last 6 months, with a median target of $83.5.

Here are some recent targets:

Luca Issi from RBC Capital set a target price of $62.0 on 07/07/2026
Whitney Ijem from Canaccord Genuity set a target price of $111.0 on 05/22/2026
Eric Joseph from Citigroup set a target price of $75.0 on 05/19/2026
Jason Zemansky from B of A Securities set a target price of $80.0 on 05/19/2026
Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $50.0 on 05/18/2026
Salveen Richter from Goldman Sachs set a target price of $69.0 on 05/11/2026
Matthew Harrison from Morgan Stanley set a target price of $119.0 on 05/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.